THOUSAND OAKS, Calif. ( TheStreet) -- Amgen ( AMGN) reported a 13% increase in adjusted second-quarter earnings Monday ahead of an important Food and Drug Administration meeting for its osteoporosis drug denosumab next month.

The company also raised 2009 earnings guidance and announced a marketing partnership with drug giant GlaxoSmithKline ( GSK) to sell denosumab in Europe.

Net income for the second quarter totaled $1.27 billion, or $1.25 a share, compared to net income of $906 million, or 84 cents a share, in the year-ago quarter. Income in the quarter was partially bolstered by a one-time tax benefit, the company said.

On an adjusted basis, Amgen earned $1.29 a share, above the Street's consensus estimate of $1.16 a share, according to Thomson Reuters.

June quarter revenue fell 1% year over year to $3.76 billion, but still ahead of the consensus forecast of $3.58 billion.

Amgen raised guidance on 2009 adjusted earnings to a range of $4.80 a share to $4.95 a share. Current Street consensus is at $4.57 a share. The company also said revenue for the year was coming in at the high end of its previously stated guidance range of $14.4 billion to $14.8 billion.

Amgen's second-quarter earnings report comes as the FDA is set to convene an advisory panel meeting on Aug. 13 to review the company's experimental osteoporosis drug denosumab. A key issue to be debated at the meeting will be denosumab's safety with a particular focus on any association between the drug and an increased risk of infection.

If you liked this article you might like


Goodbye CytRx, Your Game Is Over

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio